PMID- 26929970
OWN - NLM
STAT- MEDLINE
DCOM- 20161114
LR  - 20200317
IS  - 2327-2228 (Electronic)
IS  - 0363-7913 (Print)
IS  - 0363-7913 (Linking)
VI  - 99
IP  - 3
DP  - 2016 Mar 1
TI  - Concordance between Activated Partial Thromboplastin Time and Antifactor Xa Assay 
      for Monitoring Unfractionated Heparin in Hospitalized Hyperbilirubinemic 
      Patients.
PG  - 33-7
AB  - BACKGROUND: Activated partial thromboplastin time (aPTT) and antifactor Xa 
      (anti-Xa) monitoring methods for unfractionated heparin (UFH) often disagree. The 
      extent of discordance for those with elevated bilirubin remains unclear. Our 
      objective was to evaluate concordance between activated aPTT and anti-Xa methods 
      for hyperbilirubinemic patients on UFH. METHODS: This was a retrospective cohort 
      study of 26 patients hospitalized at Rhode Island Hospital between August 2014 
      and September 2014. Patients had at least one bilirubin measurement >5 mg/dL. 
      After categorizing lab values, percent agreement and kappa were used to examine 
      concordance between aPTT and anti-Xa. RESULTS: Overall percent agreement between 
      aPTT and anti-Xa was 50%. A nontherapeutic aPTT and therapeutic anti-Xa accounted 
      for 98% of all disagreement. Specifically, 76.7% of disagreement was due to a 
      subtherapeutic aPTT and a therapeutic anti-Xa. Unweighted kappa was 0.141 (95%CI: 
      0.048-0.235). CONCLUSION: Concordance between aPTT and anti-Xa values was poor in 
      hyperbilirubinemic patients.
FAU - Mahmoud, Leana
AU  - Mahmoud L
AD  - Neurocritical Care Specialist, Department of Pharmacy, Rhode Island Hospital, 
      Providence, RI.
FAU - Zullo, Andrew R
AU  - Zullo AR
AD  - Investigator, Department of Health Services, Policy, and Practice, Brown 
      University School of Public Health, Providence, RI; Clinical Pharmacist 
      Specialist, Department of Pharmacy, Rhode Island Hospital, Providence, RI.
FAU - McKaig, Donald
AU  - McKaig D
AD  - Medication Quality and Safety Specialist, Department of Pharmacy, Rhode Island 
      Hospital, Providence, RI.
FAU - Berard-Collins, Christine M
AU  - Berard-Collins CM
AD  - Director of Pharmacy, Rhode Island Hospital, The Miriam Hospital, and Bradley 
      Hospital, Providence, RI.
LA  - eng
GR  - K12 HS022998/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Observational Study
DEP - 20160301
PL  - United States
TA  - R I Med J (2013)
JT  - Rhode Island medical journal (2013)
JID - 101605827
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - RFM9X3LJ49 (Bilirubin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*therapeutic use
MH  - Bilirubin/metabolism
MH  - Factor Xa Inhibitors/metabolism/*therapeutic use
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Hyperbilirubinemia/*blood
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC7071828
MID - NIHMS1562708
OTO - NOTNLM
OT  - Activated partial thromboplastin time
OT  - Rhode Island
OT  - antifactor Xa heparin assay
OT  - hyperbilirubinemia
OT  - unfractionated heparin
EDAT- 2016/03/02 06:00
MHDA- 2016/11/15 06:00
PMCR- 2020/03/14
CRDT- 2016/03/02 06:00
PHST- 2016/03/02 06:00 [entrez]
PHST- 2016/03/02 06:00 [pubmed]
PHST- 2016/11/15 06:00 [medline]
PHST- 2020/03/14 00:00 [pmc-release]
PST - epublish
SO  - R I Med J (2013). 2016 Mar 1;99(3):33-7.